Empowered Funds LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 44,117 shares of the biopharmaceutical company’s stock after buying an additional 9,396 shares during the quarter. Empowered Funds LLC’s holdings in Gilead Sciences were worth $2,788,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Laurel Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 225.0% during the second quarter. Laurel Wealth Advisors LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 225 shares during the last quarter. Global Wealth Management Investment Advisory Inc. raised its holdings in Gilead Sciences by 66.5% in the 2nd quarter. Global Wealth Management Investment Advisory Inc. now owns 388 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 155 shares in the last quarter. RMR Wealth Builders bought a new position in Gilead Sciences in the second quarter worth about $30,000. Price Wealth LLC lifted its stake in shares of Gilead Sciences by 215.3% in the 3rd quarter. Price Wealth LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 351 shares during the period. Finally, Pacific Center for Financial Services raised its holdings in Gilead Sciences by 130.5% in the second quarter. Pacific Center for Financial Services now owns 484 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 274 shares in the last quarter. 77.87% of the stock is owned by institutional investors and hedge funds.

NASDAQ:GILD traded down $1.13 during mid-day trading on Wednesday, hitting $58.88. 558,063 shares of the company traded hands, compared to its average volume of 14,693,448. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 1.22. The stock’s fifty day moving average price is $63.23 and its 200-day moving average price is $71.49. The firm has a market cap of $75.24 billion, a price-to-earnings ratio of -250.03, a price-to-earnings-growth ratio of 0.68 and a beta of 0.55. Gilead Sciences, Inc. has a one year low of $59.40 and a one year high of $85.97.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%. Equities analysts predict that Gilead Sciences, Inc. will post 6.84 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were paid a $0.68 dividend. The ex-dividend date was Monday, September 14th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.62%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.

A number of research analysts recently issued reports on GILD shares. Oppenheimer lifted their price target on shares of Gilead Sciences from $90.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Wells Fargo & Company increased their target price on Gilead Sciences from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 19th. BMO Capital Markets upped their price target on shares of Gilead Sciences from $74.00 to $79.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 19th. SunTrust Banks increased their price objective on shares of Gilead Sciences from $73.00 to $74.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $78.00 to $80.00 in a report on Monday, August 3rd. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $77.44.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.